Modified peptides in anti-cancer vaccines: Are we eventually improving anti-tumour immunity?

Cancer Immunology, Immunotherapy

Volumn 58, Issue 7, 2009, Pages 1159-1167

  Iero, Manuela ^a   Filipazzi, Paola ^a   Castelli, Chiara ^a   Belli, Filiberto ^a   Valdagni, Riccardo ^a   Parmiani, Giorgio ^b   Patuzzo, Roberto ^a   Santinami, Mario ^a   Rivoltini, Licia ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Active immunotherapy; Colo rectal carcinoma; Heteroclytic peptides; Melanoma; Superagonist analogues

Indexed keywords

CANCER VACCINE; EPITOPE; GLYCOPROTEIN GP 100; HLA A2 ANTIGEN; HLA ANTIGEN CLASS 1; MELAN A; RECOMBINANT PROTEIN; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIGEN BINDING; ANTIGEN RECOGNITION; CANCER IMMUNIZATION; CANCER PATIENT; CELLULAR IMMUNITY; CLINICAL EFFECTIVENESS; CONFERENCE PAPER; CROSS REACTION; HLA SYSTEM; HUMAN; IMMUNOGENICITY; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; T LYMPHOCYTE; TUMOR IMMUNITY;

AMINO ACID SUBSTITUTION; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; NEOPLASMS; PEPTIDES; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTE SUBSETS;

EID: 67349156400     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-008-0610-6     Document Type: Conference Paper

References (58)

1. G Parmiani C Castelli M Santinami L Rivoltini 2007 Melanoma immunology: past, present and future Curr Opin Oncol 19 121 127 (Pubitemid 46204351)
2. SA Rosenberg JC Yang NP Restifo 2004 Cancer immunotherapy: moving beyond current vaccines Nat Med 10 9 909 915 (Pubitemid 39273730)
3. L Rivoltini P Canese V Huber M Iero L Pilla R Valenti S Fais F Lozupone C Casati C Castelli G Parmiani 2005 Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control? Expert Opin Biol Ther 5 463 476 (Pubitemid 40593331)
4. A Zippelius MJ Pittet P Batard N Rufer M de Smedt P Guillaume K Ellefsen D Valmori D Lienard J Plum HR [tmp] MacDonald DE Speiser JC Cerottini P Romero 2002 Thymic selection generates a large T cell pool recognizing a self-peptide in humans J Exp Med 195 485 494 (Pubitemid 34461301)
5. J Sprent D Lo EK Gao Y Ron 1988 T cell selection in the thymus Immunol Rev 101 173 190 (Pubitemid 18053872)
6. ES Huseby J White F Crawford T Vass D Becker C Pinilla P Marrack JW Kappler 2005 How the T cell repertoire becomes peptide and MHC specific Cell 122 247 260 (Pubitemid 41032988)
7. FM Marincola EM Jaffee DJ Hicklin S Ferrone 2000 Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance Adv Immunol 74 181 273
8. FM Marincola E Wang M Herlyn B Seliger S Ferrone 2003 Tumors as elusive targets of T-cell-based active immunotherapy Trends Immunol 24 335 342 (Pubitemid 36694884)
9. PR Rogers HM Grey M Croft 1998 Modulation of naive CD4 T cell activation with altered peptide ligands: the nature of the peptide and presentation in the context of costimulation are critical for a sustained response J Immunol 160 3698 3704 (Pubitemid 28176070)
10. A Dressel JL Chin A Sette R Gausling P Hollsberg DA Hafler 1997 Autoantigen recognition by human CD8 T cell clones: enhanced agonist response induced by altered peptide ligands J Immunol 159 4943 4951 (Pubitemid 127471031)
11. M Vergelli B Hemmer M Kalbus AB Vogt N Ling P Conlon JE Coligan H [tmp] McFarland R Martin 1997 Modifications of peptide ligands enhancing T cell responsiveness imply large numbers of stimulatory ligands for autoreactive T cells J Immunol 158 3746 3752 (Pubitemid 127488730)
12. LB Nicholson H Waldner AM Carrizosa A Sette M Collins VK Kuchroo 1998 Heteroclitic proliferative responses and changes in cytokine profile induced by altered peptides: implications for autoimmunity Proc Nat Acad Sci USA 95 264 269 (Pubitemid 28103942)
13. D Valmori JF Fonteneau CM Lizana N Gervois D Lienard D Rimoldi V Jongeneel F Jotereau JC Cerottini P Romero 1998 Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues J Immunol 160 1750 1758 (Pubitemid 28110836)
14. MR Parkhurst ML Salgaller S Southwood PF Robbins A Sette SA Rosenberg Y Kawakami 1996 Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues J Immunol 157 2539 2548 (Pubitemid 126450467)
15. L Fong Y Hou A Rivas C Benike A Yuen GA Fisher MM Davis EG Engleman 2001 Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy Proc Natl Acad Sci USA 98 8809 8814 (Pubitemid 32678109)
16. MA Morse AC Hobeika T Osada D Serra D Niedzwiecki HK Lyerly TM Clay 2008 Depletion of human regulatory T cells specifically enhances antigen specific immune responses to cancer vaccines Blood 112 610 618
17. L Rivoltini P Squarcina DJ Loftus C Castelli P Tarsini A Mazzocchi F Rini V Viggiano F Belli G Parmiani 1999 A superagonist variant of peptide MART1/Melan A27-35 elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: implication for more effective immunotherapy Cancer Res 59 301 306 (Pubitemid 29048857)
18. L Novellino C Castelli G Parmiani 2005 A listing of human tumor antigens recognized by T cells: March 2004 update Cancer Immunol Immunother 54 187 207 (Pubitemid 40174238)
19. CL Slingluff Jr VH Engelhard S Ferrone 2006 Peptide and dendritic cell vaccines Clin Cancer Res 12 2342s 2345s
20. GJ Kersh PM Allen 1996 Essential flexibility in the T-cell recognition of antigen Nature 380 495 498 (Pubitemid 26110635)
21. BD Evavold J Sloan-Lancaster KJ Wilson JB Rothbard PM Allen 1995 Specific T cell recognition of minimally homologous peptides: evidence for multiple endogenous ligands Immunity 2 663 665
22. FF Shih PM Allen 2004 T cells are not as degenerate as you think, once you get to know them Mol Immunol 40 1041 1046 (Pubitemid 38221184)
23. J Hennecke DC Wiley 2001 T cell receptor-MHC interactions up close Cell 104 1 4 (Pubitemid 32144966)
24. J Sloan-Lancaster MA Paul 1995 Significance of T-cell stimulation by altered peptide ligands in T cell biology Curr Op Immunol 7 103 109
25. ES Huseby F Crawford J White P Marrack JW Kappler 2006 Interface-disrupting amino acids establish specificity between T cell receptors and complexes of major histocompatibility complex and peptide Nat Immunol 7 1191 1199 (Pubitemid 44594315)
26. Y Kawakami S Eliyahu K Sakaguchi PF Robbins L Rivoltini JR Yannelli E Appella SA Rosenberg 1994 Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes J Exp Med 180 347 352 (Pubitemid 24181083)
27. D Valmori N Gervois D Rimoldi JF Fonteneau A Bonelo D Liénard L Rivoltini F Jotereau JC Cerottini P Romero 1998 Diversity of the fine specificity displayed by HLA-A0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide J Immunol 161 6956 6962 (Pubitemid 28562243)
28. E Jäger YT Chen JW Drijfhout J Karbach M Ringhoffer D Jäger M Arand H Wada Y Noguchi E Stockert LJ Old A Knuth 1998 Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes J Exp Med 187 265 270 (Pubitemid 28060443)
29. P Romero V Dutoit V Rubio-Godoy D Liénard D Speiser P Guillaume K Servis D Rimoldi JC Cerottini D Valmori 2001 CD8+ T-cell response to NY-ESO-1: relative antigenicity and in vitro immunogenicity of natural and analogue sequences Clin Cancer Res 7 766s 772s (Pubitemid 33600925)
30. S Bownds P Tong-On SA Rosenberg M Parkhurst 2001 Induction of tumor-reactive cytotoxic T-lymphocytes using a peptide from NY-ESO-1 modified at the carboxy-terminus to enhance HLA-A2.1 binding affinity and stability in solution J Immunother 24 1 9 (Pubitemid 32101962)
31. JL Chen PR Dunbar U Gileadi E Jäger S Gnjatic Y Nagata E Stockert DL Panicali YT Chen A Knuth LJ Old V Cerundolo 2000 Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL J Immunol 165 948 955 (Pubitemid 30484763)
32. JL Chen G Stewart-Jones G Bossi NM Lissin L Wooldridge EM Choi G Held PR Dunbar RM Esnouf M Sami JM Boulter P Rizkallah C Renner A Sewell PA van der Merwe BK Jakobsen G Griffiths EY Jones V Cerundolo 2005 Structural and kinetic basis for heightened immunogenicity of T cell vaccines J Exp Med 201 1243 1255 (Pubitemid 40629068)
33. DJ Cole DP Weil P Shamamian L Rivoltini Y Kawakami S Topalian C Jennings S Eliyahu SA Rosenberg MI Nishimura 1994 Identification of MART-1-specific T-cell receptors: T cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitope Cancer Res 54 5265 5268 (Pubitemid 24336011)
34. S Zaremba E Barzaga M Zhu N Soares KY Tsang J Schlom 1997 Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen Cancer Res 57 4570 4577 (Pubitemid 27441063)
35. M Iero P Squarcina P Romero P Guillaume E Scarselli R Cerino M Carrabba O Toutirais G Parmiani L Rivoltini 2007 Low TCR avidity and lack of tumor cell recognition in CD8(+) T cells primed with the CEA-analogue CAP1-6D peptide Cancer Immunol Immunother 56 1979 1991 (Pubitemid 47512618)
36. MA Purbhoo DH Sutton JE Brewer RE Mullings ME Hill TM Mahon J Karbach E Jäger BJ Cameron N Lissin P Vyas JL Chen V Cerundolo BK Jakobsen 2006 Quantifying and imaging NY-ESO-1/LAGE-1-derived epitopes on tumor cells using high affinity T cell receptors J Immunol 176 7308 7316 (Pubitemid 43849031)
37. AF Ochsenbein S Sierro B Odermatt M Pericin U Karrer J Hermans S Hemmi H Hengartner RM Zinkernagel 2001 Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction Nature 411 1058 1064 (Pubitemid 32612331)
38. SA Rosenberg JC Yang DJ Schwartzentruber P Hwu FM Marincola SL Topalian NP Restifo ME Dudley SL Schwarz PJ Spiess JR Wunderlich MR Parkhurst Y Kawakami CA Seipp JH Einhorn DE White 1998 Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma Nat Med 4 321 327 (Pubitemid 28144091)
39. DE Speiser P Baumgaertner V Voelter E Devevre C Barbey N Rufer P Romero 2008 Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen Proc Natl Acad Sci USA 105 3849 3854
40. C Lurquin B Lethé E De Plaen V Corbière I Théate N van Baren PG Coulie T Boon 2005 Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen J Exp Med 201 249 257 (Pubitemid 40189434)
41. J Babatz C Rollig B Lobel G Folprecht M Haack H Gunther CH Kohne G Ehninger M Schmitz M Bornhauser 2006 Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells Cancer Immunol Immunother 55 268 276 (Pubitemid 41682575)
42. TM Clay MC Custer MD [tmp] McKee M Parkhurst PF Robbins K Kerstann J Wunderlich SA Rosenberg MI Nishimura 1999 Changes in the fine specificity of gp100(209-217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue J Immunol 162 1749 1755 (Pubitemid 29307054)
43. Stuge TB, Holmes SP, Saharan S, Tuettenberg A, Roederer M, Weber JS, Lee PP (2004) Diversity and recognition efficiency of T cell responses to cancer. PLoS Med 1(2):e28, 149-160
44. N Fazilleau H Bachelez ML Gougeon M Viguier 2007 Cutting edge: size and diversity of CD4+ CD25 high Foxp3+ regulatory T cell repertoire in humans: evidence for similarities and partial overlapping with CD4+ CD25- T cells J Immunol 179 3412 3416
45. Y Kiniwa Y Miyahara HY Wang W Peng G Peng TM Wheeler TC Thompson LJ Old RF Wang 2007 CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer Clin Cancer Res 13 6947 6958
46. S Tangri GY Ishioka X Huang J Sidney S Southwood J Fikes A Sette 2001 Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide J Exp Med 194 833 846 (Pubitemid 32983018)
47. CS Houghton ME Engelhorn C Liu D Song P Gregor PO Livingston F Orlandi JD Wolchok J [tmp] McCracken AN Houghton JA Guevara-Patiño 2007 Immunological validation of the EpitOptimizer program for streamlined design of heteroclitic epitopes Vaccine 25 5330 5342 (Pubitemid 46977537)
48. H Singh-Jasuja NP Emmerich HG Rammensee 2004 The Tübingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy Cancer Immunol Immunother 53 187 195 (Pubitemid 38328041)
49. O Hamid JC Solomon R Scotland M Garcia S Sian W Ye SL Groshen JS Weber 2007 Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease Clin Cancer Res 13 215 222 (Pubitemid 46121871)
50. C Casati C Camisaschi F Rini F Arienti L Rivoltini F Triebel G Parmiani C Castelli 2006 Soluble human LAG-3 molecule amplifies the in vitro generation of type 1 tumor-specific immunity Cancer Res 66 4450 4460
51. M Kim HB Moon K Kim KY Lee 2006 Antigen dose governs the shaping of CTL repertoires in vitro and in vivo Int Immunol 18 435 444 (Pubitemid 43329605)
52. S Yang GP Linette S Longerich FG Haluska 2002 Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2 M is correlated to TCR avidity J Immunol 169 531 539 (Pubitemid 34686176)
53. MP Colombo S Piconese 2007 Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy Nat Rev Cancer 7 880 887 (Pubitemid 350006256)
54. P Serafini I Borrello V Bronte 2006 Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression Semin Cancer Biol 16 53 65 (Pubitemid 43139709)
55. P Filipazzi R Valenti V Huber L Pilla P Canese M Iero C Castelli L Mariani G Parmiani L Rivoltini 2007 Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine J Clin Oncol 25 2546 2553 (Pubitemid 47041228)
56. RH Schabowsky S Madireddi R Sharma ES Yolcu H Shirwan 2007 Targeting CD4+ CD25+ FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy Curr Opin Investig Drugs 8 1002 1008
57. C De Santo P Serafini I Marigo L Dolcetti M Bolla P Del Soldato C Melani C Guiducci MP Colombo M Iezzi P Musiani P Zanovello V Bronte 2005 Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination Proc Natl Acad Sci USA 102 4185 4190 (Pubitemid 40388577)
58. Y Nefedova M Fishman S Sherman X Wang AA Beg DI Gabrilovich 2007 Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells Cancer Res 67 11021 11028 (Pubitemid 350145932)